These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 22500861)

  • 21. Ipilimumab: a promising immunotherapy for melanoma.
    Thumar JR; Kluger HM
    Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma].
    Ladányi A; Balatoni T
    Magy Onkol; 2013 Jun; 57(2):100-7. PubMed ID: 23795355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
    Savoia P; Astrua C; Fava P
    Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
    Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
    Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.
    Peggs KS; Quezada SA
    Expert Rev Anticancer Ther; 2010 Nov; 10(11):1697-701. PubMed ID: 21080797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
    Wolchok JD; Hodi FS; Weber JS; Allison JP; Urba WJ; Robert C; O'Day SJ; Hoos A; Humphrey R; Berman DM; Lonberg N; Korman AJ
    Ann N Y Acad Sci; 2013 Jul; 1291(1):1-13. PubMed ID: 23772560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ipilimumab treatment of metastatic melanoma].
    Ghasemi H; Schmidt H; Stolle LB
    Ugeskr Laeger; 2015 Jan; 177(2A):108-9. PubMed ID: 25612993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
    Fong L; Small EJ
    J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
    Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
    J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety of nivolumab for the treatment of metastatic melanoma.
    O'Reilly A; Larkin J
    Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.
    Berman D; Parker SM; Siegel J; Chasalow SD; Weber J; Galbraith S; Targan SR; Wang HL
    Cancer Immun; 2010 Nov; 10():11. PubMed ID: 21090563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):811-26. PubMed ID: 27403706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ipilimumab in advanced melanoma: reports of long-lasting responses.
    Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
    Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.
    Ranganath HA; Panella TJ
    J Immunother; 2015 Jun; 38(5):211. PubMed ID: 25962109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ipilimumab: a guide to its use in advanced melanoma.
    Lyseng-Williamson KA; Sanford M
    Am J Clin Dermatol; 2012 Oct; 13(5):349-54. PubMed ID: 22849352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy).
    Bakacs T; Mehrishi JN; Szabó M; Moss RW
    Pharmacol Res; 2012 Aug; 66(2):192-7. PubMed ID: 22503629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.